Abstract:Bevacizumab has been widely used in tumor targeting therapy, while the most common adverse reaction is renal impairment, manifested as proteinuria. The main mechanisms may include interfering podocytesendothelial vascular endothelial growth factor(VEGF) axis signals, increasing glomerular pressure caused by secondary hypertension, subacute renal thrombotic microangiopathy caused by endothelial damage and so on. Thrombotic microangiopathy is the main renal pathological type, and other rare types include glomerular lesions, renal interstitial disease, and benign renal arteriolar nephrosclerosis. Therefore, urine protein excretion and renal function should be closely monitored during bevacizumab treatment period for timely treatment, dose reduction or even withdrawal if necessary to ensure renal function.

Key words:Bevacizumab,Renal impairment,Proteinuria,Renal pathology